Ads
related to: alk lymphoma kinase 2 deficiency causes and treatment pictures of cancer- Patient Characteristics
See Which Patient Types Are Fit
For This FDA-Approved Treatment
- Efficacy & Safety Data
Review The Clinical Trial Results
Including Subgroup Analyses
- Register for Updates
Stay Informed About The Latest
Clinical Data Updates & More
- View Dosing Information
Access The Dosing Schedule
& Administration Info
- Patient Characteristics
Search results
Results From The WOW.Com Content Network
Anaplastic lymphoma kinase (ALK) was originally discovered in 1994 [5] [7] in anaplastic large-cell lymphoma (ALCL) cells. ALCL is caused by a (2;5)(p23:q35) chromosomal translocation that generates the fusion protein NPM-ALK, in which the kinase domain of ALK is fused to the amino-terminal part of the nucleophosmin (NPM) protein.
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. [1] They fall under the category of tyrosine kinase inhibitors , which work by inhibiting proteins involved in the abnormal growth of tumour cells.
ALK, i.e. anaplastic lymphoma kinase, is a protein product of the ALK gene located on chromosome 2. In ALK-positive ALCL, a portion of the ALK gene has merged with another site on the same or different chromosome to form a chimeric gene consisting of part of the new site and part of the ALK gene coding for ALK's activity. [4]
ALK+ large B-cell lymphoma is a type of lymphoma. [ 1 ] [ 2 ] : 378 It was first reported in 1997. [ 2 ] : 378 [ 3 ] [ 4 ] It is a rare, aggressive large B-cell process that shows ALK expression.
The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). [ 7 ] In addition to cure-directed treatment, people can benefit from self-care to manage symptoms.
Mutations in the anaplastic lymphoma kinase (ALK) oncogene can be inherited and are a major cause of neuroblastoma. [2] These mutations occur in approximately 5-15% of neuroblastoma cases. [2] ALK has recently been discovered as a molecular target of chemotherapy in the treatment of neuroblastoma patients. Drugs that target ALK are referred to ...
Ads
related to: alk lymphoma kinase 2 deficiency causes and treatment pictures of cancercareinfo.mayoclinic.org has been visited by 100K+ users in the past month